Centessa Pharmaceuticals CNTA 深 沪
等待开盘 10-08 09:30:00 美东时间
40.50
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 40.50
- 总市值 62.67亿
- 52周最高 40.56
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 13.22
- 委 比 0.00%
- 总股本 1.55亿
- 历史最高 40.56
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.885
- 每 手 1
- 风险率 6.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多今年已豪掷超200亿美元！礼来CEO：将瞄准制药“空白领域”，继续寻求更大规模并购
礼来首席执行官戴夫·里克表示，投资者可以预期，礼来公司将推进规模更大的交易，因为该公司正在科学界的“空白领域”广泛搜寻资产。
09-29 13:44
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
LB Pharmaceuticals Inc announced the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer. Dr. Kozauer brings over two decades of experience in neuropsychiatric drug development, including schizophrenia, mood disorders, and neurodegenerative diseases. She previously led clinical development at Intra-Cellular Therapies and Centessa Pharmaceuticals. LB Pharmaceuticals is advancing its Phase 3 NOVA-2 trial for LB-102, a potential first be...
09-15 12:00
半年卖了1800亿元，礼来带飞减重市场
文｜《财经》记者 凌馨 研究员 丁宁 编辑 | 王小 替尔泊肽给了礼来寻找下一个增长曲线的底气 2026年8月5日，礼来发布二季度财报...
08-11 11:25
百亿美金并购新狂潮背后
原标题：百亿美金并购新狂潮背后 又一笔百亿美元级并购诞生。 7月6日，Vertex宣布以每股85美元、总价约100亿美元的全现金交易，正式将专注于内分泌罕见病...
07-08 10:19
Record-setting healthcare M&A activity to extend through H2: PwC
Healthcare dealmaking is already at the highest level since the pandemic, and the momentum is expected to continue into H2 2026, driven by looming patent cliffs and consumer demand for areas such as w...
06-26 01:59
礼来完成对Centessa Pharmaceuticals的收购 布局嗜睡症治疗领域
礼来（LLY）完成对临床阶段生物制药企业森特萨制药（CNTA）的收购，聚焦后者的食欲素2受体激动剂管线，发力发作性睡病等觉醒-睡眠障碍、相关神经类疾病的创新疗法...
06-24 20:56
礼来78亿美元收购Centessa Pharma案获高等法院批准
礼来78亿美元收购Centessa制药的交易已获得高等法院批准，扫清核心监管障碍，向落地迈出关键一步。 Centessa股东可获每股38.00美元现金，以及最...
06-23 14:46
Centessa Pharmaceuticals' Proposed $38/Share Acquisition By Eli Lilly Receives High Court Of Justice Of England And Wales Approval
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, which entered into a definitive agreement on March 31, 2026 relating to its proposed acquisition by Eli Lilly...
06-23 04:08
